106 related articles for article (PubMed ID: 26723895)
1. Treatment trends for clinically localised prostate cancer. National population analysis: GESCAP group.
Miñana B; Rodríguez-Antolín A; Gómez-Veiga F; Hernández C; Suárez JF; Fernández-Gómez JM; Unda M; Burgos J; Alcaraz A; Rodríguez P; Moreno C; Pedrosa E; Cózar JM;
Actas Urol Esp; 2016 May; 40(4):209-16. PubMed ID: 26723895
[TBL] [Abstract][Full Text] [Related]
2. Diagnosis and treatment for clinically localized prostate cancer. Adherence to the European Association of Urology clinical guidelines in a nationwide population-based study - GESCAP group.
Gómez-Veiga F; Rodríguez-Antolín A; Miñana B; Hernández C; Suárez JF; Fernández-Gómez JM; Unda M; Burgos J; Alcaraz A; Rodríguez P; Medina R; Castiñeiras J; Moreno C; Pedrosa E; Cózar JM;
Actas Urol Esp; 2017; 41(6):359-367. PubMed ID: 28285790
[TBL] [Abstract][Full Text] [Related]
3. Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow.
Prescrire Int; 2012 Oct; 21(131):242-8. PubMed ID: 23185849
[TBL] [Abstract][Full Text] [Related]
4. Initial management of prostate cancer: first year experience with the Norwegian National Prostate Cancer Registry.
Hernes E; Kyrdalen A; Kvåle R; Hem E; Klepp O; Axcrona K; Fosså SD
BJU Int; 2010 Mar; 105(6):805-11; discussion 811. PubMed ID: 19735258
[TBL] [Abstract][Full Text] [Related]
5. Optimizing D'Amico risk groups in radical prostatectomy through the addition of magnetic resonance imaging data.
Algarra R; Zudaire B; Tienza A; Velis JM; Rincón A; Pascual I; Zudaire J
Actas Urol Esp; 2014 Nov; 38(9):594-9. PubMed ID: 24791621
[TBL] [Abstract][Full Text] [Related]
6. [Comparison of the Biochemical Recurrence risk between Radical Prostatectomy and Brachytherapy in the treatment of low- and intermediate-risk prostate cancer].
Martínez PF; Belisle DF; Cristallo C; Tobía I; Damia O; Villamil W; Giudice CR
Arch Esp Urol; 2015 Oct; 68(8):655-60. PubMed ID: 26437328
[TBL] [Abstract][Full Text] [Related]
7. Influence of demographic and tumour variables on prostate cancer treatment with curative intent in Spain. Results of the 2010 national prostate cancer registry.
Martínez-Jabaloyas JM; Castelló-Porcar A; González-Baena AC; Cózar-Olmo JM; Miñana-López B; Gómez-Veiga F; Rodriguez-Antolín A;
Actas Urol Esp; 2016 Oct; 40(8):485-91. PubMed ID: 27260350
[TBL] [Abstract][Full Text] [Related]
8. Management of Localised Prostate Cancer in Kidney Transplant Patients: A Systematic Review from the EAU Guidelines on Renal Transplantation Panel.
Hevia V; Boissier R; Rodríguez-Faba Ó; Fraser-Taylor C; Hassan-Zakri R; Lledo E; Regele H; Buddde K; Figueiredo A; Olsburgh J; Breda A
Eur Urol Focus; 2018 Mar; 4(2):153-162. PubMed ID: 29921544
[TBL] [Abstract][Full Text] [Related]
9. Three-year interim results of overall and progression-free survival in a cohort of patients with prostate cancer (GESCAP group).
Cózar JM; Miñana B; Gómez-Veiga F; Rodríguez-Antolín A;
Actas Urol Esp (Engl Ed); 2019; 43(1):4-11. PubMed ID: 29891440
[TBL] [Abstract][Full Text] [Related]
10. Adherence to the lymphadenectomy recommendations of the 2009 clinical guidelines in the 2010 National Prostate Cancer Registry.
Herranz Amo F; Hernández Fernández C; Cózar Olmo JM; Miñana López B; Gómez-Veiga F; Rodríguez-Antolín A; Pedrosa E;
Actas Urol Esp; 2015 Nov; 39(9):546-52. PubMed ID: 26096016
[TBL] [Abstract][Full Text] [Related]
11. [EAU guidelines on prostate cancer. Part I: screening, diagnosis, and treatment of clinically localised disease].
Heidenreich A; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Mottet N; Schmid HP; van der Kwast T; Wiegel T; Zattoni F
Actas Urol Esp; 2011 Oct; 35(9):501-14. PubMed ID: 21757259
[TBL] [Abstract][Full Text] [Related]
12. Is clinical stage T2c prostate cancer an intermediate- or high-risk disease?
Klaassen Z; Singh AA; Howard LE; Feng Z; Trock B; Terris MK; Aronson WJ; Cooperberg MR; Amling CL; Kane CJ; Partin A; Han M; Freedland SJ
Cancer; 2015 May; 121(9):1414-21. PubMed ID: 25492369
[TBL] [Abstract][Full Text] [Related]
13. Prostate cancer incidence and newly diagnosed patient profile in Spain in 2010.
Cózar JM; Miñana B; Gómez-Veiga F; Rodríguez-Antolín A; Villavicencio H; ; Cantalapiedra A; Pedrosa E
BJU Int; 2012 Dec; 110(11 Pt B):E701-6. PubMed ID: 22989066
[TBL] [Abstract][Full Text] [Related]
14. Radical prostatectomy vs radiation therapy and androgen-suppression therapy in high-risk prostate cancer.
Westover K; Chen MH; Moul J; Robertson C; Polascik T; Dosoretz D; Katin M; Salenius S; D'Amico AV
BJU Int; 2012 Oct; 110(8):1116-21. PubMed ID: 22540922
[TBL] [Abstract][Full Text] [Related]
15. Evolution and outcomes of 3 MHz high intensity focused ultrasound therapy for localized prostate cancer during 15 years.
Thüroff S; Chaussy C
J Urol; 2013 Aug; 190(2):702-10. PubMed ID: 23415962
[TBL] [Abstract][Full Text] [Related]
16. [Comparative study of radical prostatectomy versus external beam radiotherapy (75.6 Gy) combined with hormone therapy for prostate cancer of intermediate D'Amico risk classification].
Boissier R; Karsenty G; Muracciole X; Daniel L; Delaporte V; Maurin C; Coulange C; Lechevallier E
Prog Urol; 2013 Sep; 23(10):861-8. PubMed ID: 24034798
[TBL] [Abstract][Full Text] [Related]
17. A retrospective study of the treatment of locally advanced prostate cancer by six institutions in eastern and north-eastern Japan.
Hachiya T; Akakura K; Saito S; Shinohara N; Sato K; Harada M; Kato T; Okada K
BJU Int; 2005 Mar; 95(4):534-40. PubMed ID: 15705075
[TBL] [Abstract][Full Text] [Related]
18. Prostate Specific Antigen (PSA) as Predicting Marker for Clinical Outcome and Evaluation of Early Toxicity Rate after High-Dose Rate Brachytherapy (HDR-BT) in Combination with Additional External Beam Radiation Therapy (EBRT) for High Risk Prostate Cancer.
Ecke TH; Huang-Tiel HJ; Golka K; Selinski S; Geis BC; Koswig S; Bathe K; Hallmann S; Gerullis H
Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27834929
[TBL] [Abstract][Full Text] [Related]
19. Factors associated with treatment received by men diagnosed with prostate cancer in Queensland, Australia.
Baade PD; Youlden DR; Gardiner RA; Ferguson M; Aitken JF; Yaxley J; Chambers SK
BJU Int; 2012 Dec; 110(11 Pt B):E712-9. PubMed ID: 23017157
[TBL] [Abstract][Full Text] [Related]
20. Prostate cancer before renal transplantation: A multicentre study.
Chahwan C; Doerfler A; Brichart N; Bouyé S; Culty T; Iselin C; Pfister C; Sallusto F; Salomon L; Verhoest G; Viart L; Tillou X;
Prog Urol; 2017 Mar; 27(3):166-175. PubMed ID: 28237495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
